These findings suggest that a compensatory mechanism may be activated in other insulin responsive tissues, potentially including non-insulin dependent signalling pathways, to combat systemic glucose intolerance when there are defects in insulin receptor signalling in the AT from birth. The gene discussed is INS; the disease is Glucose intolerance.